Peptide receptor radionuclide therapy with 177Lu-DOTATATE: the IEO phase I-II study
Peptide receptor radionuclide therapy with 177Lu-DOTATATE: the IEO phase I-II study is a paper indexed in ScholarIQ from OpenAlex.
How many citations does Peptide receptor radionuclide therapy with 177Lu-DOTATATE: the IEO phase I-II study have?
Peptide receptor radionuclide therapy with 177Lu-DOTATATE: the IEO phase I-II study has 423 citations in the OpenAlex counts ScholarIQ stores.
When was Peptide receptor radionuclide therapy with 177Lu-DOTATATE: the IEO phase I-II study published?
Peptide receptor radionuclide therapy with 177Lu-DOTATATE: the IEO phase I-II study has 2011 year in the ScholarIQ index.
What is the open-access status of Peptide receptor radionuclide therapy with 177Lu-DOTATATE: the IEO phase I-II study?
Peptide receptor radionuclide therapy with 177Lu-DOTATATE: the IEO phase I-II study has closed oa status in the ScholarIQ index.
What is the DOI of Peptide receptor radionuclide therapy with 177Lu-DOTATATE: the IEO phase I-II study?
The DOI for Peptide receptor radionuclide therapy with 177Lu-DOTATATE: the IEO phase I-II study is on the source record.
What is the PMID of Peptide receptor radionuclide therapy with 177Lu-DOTATATE: the IEO phase I-II study?
The PMID for Peptide receptor radionuclide therapy with 177Lu-DOTATATE: the IEO phase I-II study is on the source record.
What is the OpenAlex record for Peptide receptor radionuclide therapy with 177Lu-DOTATATE: the IEO phase I-II study?
The OpenAlex for Peptide receptor radionuclide therapy with 177Lu-DOTATATE: the IEO phase I-II study is on the source record.